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Abstract
Background: Cancer is a rapidly increasing problem in developing countries. Access, quality and efficiency of
cancer services in developing countries must be understood to advance effective cancer control programs. Health
services research can provide insights into these areas.
Discussion: This article provides an overview of oncology health services in developing countries. We use selected
examples from peer-reviewed literature in health services research and relevant publicly available documents. In
spite of significant limitations in the available data, it is clear there are substantial barriers to access to cancer
control in developing countries. This includes prevention, early detection, diagnosis/treatment and palliation. There
are also substantial limitations in the quality of cancer control and a great need to improve economic efficiency.
We describe how the application of health data may assist in optimizing (1) Structure: strengthening planning,
collaboration, transparency, research development, education and capacity building. (2) Process: enabling follow-up,
knowledge translation, patient safety and quality assurance. (3) Outcome: facilitating evaluation, monitoring and
improvement of national cancer control efforts. There is currently limited data and capacity to use this data in
developing countries for these purposes.
Summary: There is an urgent need to improve health services for cancer control in developing countries. Current
resources and much-needed investments must be optimally managed. To achieve this, we would recommend
investment in four key priorities: (1) Capacity building in oncology health services research, policy and planning
relevant to developing countries. (2) Development of high-quality health data sources. (3) More oncology-related
economic evaluations in developing countries. (4) Exploration of high-quality models of cancer control in
developing countries. Meeting these needs will require national, regional and international collaboration as well as
political leadership. Horizontal integration with programs for other diseases will be important.
Background
2005 estimates suggest 13% of all deaths globally are
from cancer [1]. Of the estimated 7.6 million cancer
deaths worldwide in 2007, 62% were in developing
countries [2]. Given the population boom and aging of
the population in developing countries, Parkin et al have
projected a 75% increase in cancer incidence in the
developing world between the year 2000 and 2020 [3].
In order to prevent and manage this change in cancer
incidence, significant organization and infrastructure is
required to prevent, screen, treat and palliate cancer. As
a result, the implications to health services delivery in
developing countries are enormous.
Health services research largely concerns itself with
the factors influencing the need for health services,
access to these services, quality and economic efficiency,
in addition to the health outcomes of the individuals
and populations involved [4]. Other health service ele-
ments of great importance to developing countries are
equity and sustainability. The purpose of this article is
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health services in developing countries and to highlight
data needs and current gaps in knowledge. We will
focus on elements of access, quality and efficiency. We
will then illustrate how filling current gaps in knowledge
can facilitate optimization of much-needed cancer-
related investment in health care systems and national
cancer control strategies.
Discussion
Describing Quality of Cancer Control in Developing
Countries
We consider the four principal approaches of cancer
control to be cancer prevention, early detection, diagno-
sis/treatment and palliation, as described by the World
Health Organization [5]. We will describe what is
known about the quality of oncology services for cancer
control in developing countries in terms of Donabe-
dian’s framework [6]. Donabedian describes quality
assessment in terms of structure, process and outcome
[6]. Structure refers to the attributes of the setting
where care is delivered. This includes material resources,
human resources and organizational structure. To assess
structure, one must consider how well the health care
system interfaces with society and individuals in society
[7]. For example, a current structural problem for devel-
oping countries is a medical structure historically
designed to manage communicable disease, nutritional
deficiencies, child health and maternal health. These
health care structures are now faced with the additional
burden of chronic diseases such as cancer, cardiovascu-
lar disease, diabetes and chronic respiratory disease.
These chronic diseases share common risk factors,
emphasizing the importance of integration between pre-
vention programs targeting them. Process refers to what
is actually done while care is provided and received.
This includes patient’s health care seeking activities, the
diagnostic process, treatment recommendation and
treatment delivery. Outcome refers to the effects of care
on the health status of patients and populations. Out-
comes may be medical parameters (e.g. survival after
cancer treatment), quality of life, patient satisfaction,
equity or economic efficiency [7]. Outcomes also include
measures such as changes in patient knowledge and
individual’s behaviour.
Structure of Oncology Services in Developing Countries
There is a limited but growing body of literature
describing the current status of cancer treatment
resources, particularly for radiation therapy, in develop-
ing countries. The emerging picture demonstrates
extreme limitation of human resources, physical
resources and equipment. Taking into account the
annual incidence of cancer in developing countries,
Barton et al found that radiation machine supply was in
general inadequate to meet demand [8]. Machine supply
in Africa was sufficient to meet an estimated 18% of the
need for radiation (155 megavoltage machines available,
842 needed in total). For 12 countries in the Asia-Pacific
region with available data (including India and China),
machine supply was sufficient to meet an estimated 23%
of the current need (1147 available, 4936 needed). Sig-
nificant shortfalls were also found in Latin America and
Eastern Europe. This data highlights just one example of
the potential for mismatch between patient need and
treatment availability.
Available information suggests there is an overall
shortage of health care workers in Low- and Middle-
Income Countries, as well as massive disparities between
the rich and poor regions of the world. The World Bank
defines Low-Income Countries as those with a 2008
gross national income (GNI) per capita of US$975 or
less. Lower-Middle-Income and Upper-Middle-Income
Countries are defined as those with a GNI per capita of
US$976 - $3,855 and US$3,856 - $11,905 respectively
[9]. These groupings provide an indication of the range
of economic situations among developing countries. For
reference, High-Income Countries are those with a GNI
per capita of US$11,906 or more. High-Income coun-
tries of the world are largely in North America and Eur-
ope; other High-Income Countries include Japan and
Australia. Europe has 11 times the number of nurses
per population compared to South-East Asia and 7
times the number of doctors [10]. North America, on
average, has 10 times more nurses per population than
countries in South America [11].
Due to limited data in many developing countries, lit-
tle is known regarding capacity for treatment with che-
motherapy and surgery, capacity for cancer prevention,
early detection and other services. It is reasonably
assumed that human capacity for these activities is
extremely limited given the global shortage of human
resources for health care in developing countries.
Narcotics such as morphine are irreplaceable for con-
trolling severe pain from cancer and other serious medi-
cal conditions. However, global morphine consumption
trends provide evidence of gross under-utilization of
narcotics for pain control in many Low-Income and
Middle-Income Countries [12]. For example, in 2004,
Canada reported 64.180 mg morphine consumed per
capita, compared to 0.420 mg per capita for Peru, 0.020
mg per capita for Indonesia and 0.001 mg per capita for
Mozambique [12].
Publicly available data regarding access to drugs for
cancer therapy is limited. A 2001 country-level survey
by the World Health Organization found only 22% of
African countries reported availability of anti-cancer
drugs, 43% in the South East Asia region and 57% in
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there are significant limitations to access in many devel-
oping countries to essential drugs for chronic diseases
other than cancer, it is quite likely that access to cancer
drugs is at least as significant a problem [14,15]. Addi-
tional challenges unique to cancer drugs include the
need for extra safety equipment for pharmacy staff pre-
paring them for administration. This equipment can be
quite costly. Also, some cancer drug therapies require
predictive tests prior to use, for instance, the common
need for hormone receptor status prior to hormone
therapy for breast cancer. This poses an additional bar-
rier due to issues of cost and quality control.
The exact number of men, women and children dying
of cancer without appropriate diagnosis, treatment, early
detection or palliative care is unknown. However, avail-
able information suggests that the number is probably
staggering. The role of social, economic and political
factors such as the impact of a limited state presence in
health issues or wide-spread poverty in explaining dispa-
rities such as these is not always known. A political
economy approach that considers the role of these fac-
tors warrants careful thought.
An Illustration: The Situation in Tanzania
Tanzania is a Low-Income Country. In 2008, it had a
population of 42.5 million people and an estimated
21,180 new cancers [16,17]. Resources to manage this
significant burden of cancer are limited. For example,
nation-wide, there is 1 medical oncologist, 4 radiation
oncologists, 2 physicists and an estimated 7 pathologists.
No surgeon’s practice is dedicated solely to oncology.
These human resources are extremely limited compared
to actual need. For perspective, in Canada, a radiation
oncologist would typically see 250 new patients per
year. Given at least half of East African cancer patients
will need radiation by one conservative estimate, if each
Tanzanian radiation oncologist saw 250 new patients
per year, this would place the number of radiation
oncologists in Tanzania dramatically below the esti-
mated need [8].
Breast and cervix cancer are the most common killers
due to cancer among Tanzanian women. They contri-
bute approximately 40-50% of all new cancer cases seen
at the Ocean Road Cancer Institute, the only specialized
cancer treatment institute in Tanzania. At present, there
is no national cancer screening program for cervix,
breast or other types of cancer. There are only two
radiotherapy machines in the country, even though one
estimate suggests a need for 45 [8]. Capacity for cancer
screening and staging is limited. There are only three
mammography units, an estimated five CT scanners and
one MRI nationwide. Palliative services are only avail-
able in a few towns and three hospitals with the use of
morphine limited by national policies. Finally, there is
no formal training program within Tanzania for any dis-
cipline of oncology, forcing candidates to travel abroad,
often to South Africa or Europe for training.
Fortunately, many agencies are partnering in the
development of cancer control capacity in Tanzania. For
instance, the International Atomic Energy Agency
(IAEA) Program of Action for Cancer Therapy (PACT)
has been involved in assessing needs for cancer control,
planning, building human capacity and developing phy-
sical resources.
Limitations in Quality and Access to Cancer Services in
Developing Countries
In Low- and Middle-Income Countries, access to cancer
care is often poor. The availability of trained human
resources and physical resources are fundamental pro-
blems in cancer control among developing countries.
However, other factors also limit access to services in
developing countries. Penchansky and Thomas’ frame-
work of access to care fittingly describes some of these.
In addition to availability, they describe spatial accessi-
bility, acceptability, affordability and accommodation
[18]. Mackillop highlights a sixth dimension, awareness
[19]. Equitable access to cancer control in developing
countries is a prerequisite to equitable quality of care
[20].
The dimensions of access described by Penchansky,
Thomas and Mackillop must be further characterized
on national and regional levels for cancer control efforts
in limited-resource countries to be optimally suited to
their environments. For instance, although the effect of
geography on spatial accessibility to cancer treatments
has not been sounded in developing countries, it is
probably a significant barrier to access. Even in High-
Income Countries, distances as short as dozens of kilo-
metres from the patient’s home to the radiation therapy
centre may be associated with less use of radiation or
fewer daily treatments per patient treated [21,22]. In
many poor countries, cancer treatments such as radia-
tion are only available at a few sites nationally and often
in just one city [23-25]. This is important to note as for
the poor, travel costs may exhaust any financial reserve
before the first cancer treatment is offered.
Acceptability of treatment may be limited by values
surrounding loss of hair or fertility during chemotherapy
or loss of organs due to surgery (e.g. mastectomy for
breast cancer). These values have rarely been described
or quantified in developing countries [26]. Stigma from
cancer, cultural factors, personal beliefs, fatalism or fear
of treatment may lead to patient-related delay in treat-
ment [26-29]. It is quite likely that many of these same
factors would also prevent patients in developing coun-
tries from seeking treatment at all. Acceptability issues
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example, embarrassment or fear of pain may keep
young Brazilian women from seeking cervical cancer
screening [30].
Public awareness campaigns and government health
programs for developing countries have often been lar-
gely geared towards communicable diseases [31]. The
potential impact of building awareness of principles of
cancer treatment, prevention and early detection on
access to care in developing countries may be tremen-
dous. For example, in Lahore, Pakistan, only 5% of
women surveyed at a tertiary care hospital were aware
that screening existed for cervix cancer and only 2.6%
h a de v e rr e c e i v e dap a pt e s t[ 3 2 ] .O n l yo n et h i r do f
patients seeking medical attention for cancer at a large
cancer clinic in Delhi, India believed that cancer could
be cured [33]. The situation may be complicated by
modest or limited health care worker training in basic
principles of oncology and sometimes even a lack of
awareness of the curability of cancer [34,35].
Beyond building awareness among the general public,
creating an awareness of the need for cancer services in
developing countries among government officials, medi-
cal educators, policy makers and key advocates in the
public and press is crucial. The health services research
community has an important role to play in improving
awareness on these fronts, informing communications
and targeting messages as effectively as possible. Organi-
zations such as the International Union Against Cancer
(UICC), the IAEA, the American Cancer Society and the
World Health Organization (WHO) have taken leader-
ship in this area, though a substantial effort is still
needed to expand awareness among all parties.
Process of Oncology Services in Developing Countries
Little is known about both the process and outcome of
cancer control efforts in most developing countries
despite the importance of this information (see below).
Descriptions of patterns of cancer treatment in develop-
ing countries are hard to find. For example, there is
only one report in the indexed literature examining pal-
liative radiation use in Africa. While there is extensive
clinical trial evidence supporting shorter and less costly
palliative treatments for bone metastases, this report
suggests that 77% of surveyed centers use longer treat-
ments, despite limited resources [36]. Information on
the equity of the treatment process in this or other set-
tings is not available in the literature to our knowledge.
An IAEA study of patterns of practice in developing
Central and Eastern European countries found variations
in use of radiation for lung cancer, including schedules
of palliative radiation and approaches for radical treat-
ment. Concurrent chemo-radiation is considered the
optimal curative treatment for unresected advanced
non-small cell lung cancer [37]. Among the developing
countries participating in this study, sequential chemo-
radiation (57%) was used far more often than concur-
rent chemo-radiation (10%) for non-small cell lung can-
cer, the opposite of reported patterns of practice in the
United States [38,39].
A patterns of care study from China found that 92%
of radiation for breast cancer was given as post-mastect-
omy radiation therapy (PMRT), suggesting little use of
breast conserving therapy among clinicians surveyed
[40]. Though low survey response rates limit interpreta-
tion of these results, it appears that the non-standard
indication of PMRT for centrally or medially located
cancers ≤5 cm in size without lymph node spread is
common, as is radiation to the internal mammary
lymph nodes which is of unproven benefit.
T h e r ei sl i t t l ek n o w nr e g a r d i n gp a t i e n ts a f e t ya n d
quality control during cancer treatment in developing
countries. Much of the available information comes
from the IAEA. They have been involved for years in
quality control efforts related to radiation therapy in
developing countries as well as various other programs
to improve cancer management in developing countries
[41,42]. For example, an IAEA audit of radiation
machine dosimetry found 16% of audited radiation
beams in various developing countries did not meet the
+/-5% dose acceptance limit on the first test of radiation
dosimetric standards [41]. Doses beyond this +/-5%
acceptance limit have been associated with severe and
even lethal toxicity [43]. 93% of radiation beams met
standards by the second iteration of the audit. These
data highlight the importance of technical audit in
developing countries, as in all countries. While dosime-
try appears to be typically acceptable, a small minority
of cases can be identified where patient safety is a con-
cern and changes must be made to local practice.
Outcomes of Cancer Services in Developing Countries
Available data from developing countries suggests high
mortality rates for patients with cancer compared to
High-Income Countries [44]. Often five-year survival for
Low-Income Countries is less than half that seen in
more developed countries [44,45]. The variation in sur-
vival may be related to differences in resource availabil-
ity as well as other dimensions of access and quality of
cancer treatment, early detection and prevention [45].
Inequities in survival for groups within individual devel-
oping countries have not been explored to our knowl-
edge but are probably substantial.
Outcomes of cancer prevention strategies have been
investigated in numerous developing country settings,
particularly for cervix cancer screening and also breast
cancer early detection and tobacco control [46-51].
These outcome studies suggest many of these strategies
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1.7 million cancer deaths in Low- and Middle-Income
Countries were due to potentially preventable causes in
2001 alone [52].
Little is known about other cancer-related outcomes
in developing countries such as toxicity of treatment,
quality of life, patient satisfaction, equity and economic
efficiency. The lack of information on the economic effi-
ciency of most cancer treatments and many preventive
measures is of note. Resources are limited in developing
countries and choosing the most cost-effective measures
is a very important consideration.
Information Needs to Improve Cancer Control in
Developing Countries
Clearly, investment in health care systems in developing
countries is required. For oncology, this includes devel-
oping a sustainable supply of trained oncology profes-
sionals, expanding the supply of treatment equipment,
improving drug supply, physical infrastructure and orga-
nizational infrastructure for cancer control. Given lim-
ited resources, health services researchers and policy
makers must explore how these much-needed invest-
ments can be best directed for optimal results. For
example, the London Declaration on Cancer Control in
Africa endorses national cancer control plans that are
‘evidence based, priority driven and resource appropri-
ate’. This will require cancer-related health services
research with broad local and international collabora-
tions in addition to long-term investment from all par-
ties [53].
The need for better health monitoring and evaluation
data in developing countries is widely recognized. Tar-
gets set by the International Union Against Cancer
(UICC) World Cancer Declaration 2008 include
improved measurement of the global cancer burden and
measurement of the impact of cancer control interven-
tions [54]. Notably, this year, eight of the largest global
health agencies, including the World Health Organiza-
tion, Bill and Melinda Gates Foundation and the World
Bank reached a consensus on health data [55]. This con-
sensus calls for increased investment in health informa-
tion, efficiency of this investment, development of a
common data architecture, strengthening of perfor-
mance monitoring and evaluation, increased data use in
developing countries and improved data access [55].
Common information sources in developing countries
are health surveys, birth and death registration, census
data, health facility reporting systems, health surveillance
data and health administrative data [55]. These common
information sources provide information on many dis-
ease types. Given information needs across health sec-
tors, we would emphasize the importance of horizontal
integration between disease control initiatives in
contrast to solely focusing on vertical stand-alone pro-
grams. This offers the promise of strengthening the sys-
tem-wide structure of health care systems in developing
countries.
Population-based cancer registries collect information
on the occurrence of different types of cancer in a
population. The information they contain may also
include national or hospital-based information on cancer
treatment and vital status. They are one unique form of
cancer data of great importance to developing countries.
Cancer registries provide the backbone of information
infrastructure needed to perform a wide range of oncol-
ogy health services research. The population-based
information on cancer cases can be linked to other
population-based and hospital-based health data sources
to provide a rich tapestry of information on structure,
process and outcome of cancer prevention, screening,
palliation and treatment. Common sources of cancer
registry information include hospital inpatient records,
radiation treatment records, hospital records, pathology
records, haematology lab reports, autopsies, death certi-
ficates and screening programme records [56].
There are still many developing countries without a
cancer registry of sufficient quality. For instance, the
population coverage by cancer registries of sufficient
quality for inclusion in the International Agency for
Research on Cancer’s (IARC) 2007 report on global can-
cer incidence was 1% for Africa, 4% for Asia, and 4% for
South and Central America. This compares to 33% in
Europe and 80% in North America [56].
Developing cancer registries and health databases do
have their own significant costs. Stansfield et al estimate
annual per capita costs of a comprehensive health infor-
mation system of US$0.53 in Low-Income Countries
[57]. This may represent a significant health expenditure
for many Low-Income Countries, though there is evi-
dence that this investment can be cost-effective [57].
Low-Income Countries may need to rely initially on
basic estimates of cancer burden and health needs when
developing their first national cancer control plan. How-
ever, it is imperative even for these most limited
resource countries to create a timeline and vision for
the appropriate development of useful cancer data
sources.
Health Data for Quality Cancer Control in Developing
Countries: Structure
The information in cancer registries and related health
data serve many irreplaceable functions (Table 1). In
terms of improving the structure of cancer control, this
information contributes to cancer system planning that
fits well to local needs [58,59]. Resource constraints in
High-Income Country’s cancer systems have given rise
to methodologies using health information to estimate
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to these services. These methodologies provide a means
for minimizing the dual problems of over-provision
(unnecessary care) and under-provision (insufficient
care) of cancer control resources. To date, this work has
largely focused on radiation therapy [22,60-63]. These
methodologies would assist developing countries in
ensuring accessible and equitable cancer control. They
have not been widely applied to cancer control in devel-
oping countries to our knowledge.
Regularly collected health data also allows cancer con-
trol planning to be flexible and iterative. Continuous
data collection can reveal changes in needs and develop-
ment of critical health issues [64]. By monitoring for
these changes, the health care system can more effi-
ciently change to match these needs. This is an impor-
tant element for ensuring sustainability of the health
care system. Continued data collection also allows for
adjustment of the scale of programs to current capacity
and need [64].
There are now often many local, national and interna-
tional health agencies involved in health interventions in
any given developing country. Effective collaboration is
needed to ensure success. Health data on cancer pro-
vides a means of harmonizing the efforts of all groups,
most importantly in situations where opinions differ
[65]. Collection of national health data can also be help-
ful in determining how appropriate successful models
from other countries would be to national conditions
[65].
Collection and evaluation of health information pro-
motes transparency. For instance, this information can
allow greater participation of the public and other par-
ties in national and regional advocacy for changes to
health policy. It also enables national, regional and inter-
national agencies to effectively advocate for needed
resources for national cancer control by building a clear
picture of local needs [65]. It also allows for account-
ability of parties involved in provision of cancer control
to the public and funding agencies [59].
Cancer registry data and health data are crucial for
supporting national and regional research structure.
They can help define cancer research priorities, for
instance, focusing research on cancers with the greatest
burden of disease in the population or exploring the
potential cost-effectiveness of a new cancer treatment or
cancer control strategy to be studied [66]. Cancer regis-
try data may serve as the basis for epidemiological stu-
dies of cancer causation in developing countries or
identify patients with cancer for other forms of cancer
research. For instance, population-based cancer regis-
tries can facilitate studies of access to cancer care.
Cancer registries and their linked data also serve as
aids to educating health professionals such as by shaping
medical curricula to local problems. They can also serve
as an important tool in the local training of individuals
in health policy, graduate level epidemiology and health
services research. This can ultimately support an evi-
dence-based, research-informed culture of medical prac-
tice for participating developing countries. It can also
ensure a sustainable supply of workers who can utilize
health data in-country to improve the quality of national
cancer control.
Table 1 Health Data for Quality Cancer Control in
Developing Countries
Quality
Assessment
Category
Use of Health
Data to Improve
Quality
Structure Planning: National cancer control programs that are:
1. Accessible
2. Equitable
3. Flexible and iteratively planned
4. Sustainable
5. Scalable
6. Economically efficient
Collaboration:
1. Harmonization of national cancer control efforts
between groups
2. Identifying applicable models from other countries
Transparency:
1. Participation: Public involvement in decision
making
2. Advocacy: Calls for greater funding
3. Accountability: To public and funding agencies
Research Development:
1. Defining research priorities
2. Identifying research subjects
Education: Improving local medical curricula in oncology
Capacity building: Local training in health policy,
epidemiology and health services research
Process Follow-up: Ensuring follow-up for cancer screening and
treatment
Knowledge translation:
1. Identifying targets for knowledge translation
initiatives
2. Evaluation of knowledge translation initiatives
Patient safety and quality assurance: Audit of technical
process
Outcome Evaluation, monitoring and improvement of national
cancer control efforts:
1. Effectiveness
2. Accessibility
3. Equitability
4. Sustainability
5. Economic efficiency
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Countries: Process
In terms of process, cancer registries and integrated
health data systems may facilitate follow-up of indivi-
duals for screening or follow-up of cancer patients.
They can also assist in understanding the medical deci-
sion making process which can help identify opportu-
nities for knowledge translation. For instance, the study
of radiation use for bone metastasis in Africa suggests
an opportunity to reduce the number of daily radiation
treatments per patient. This would increase capacity to
treat many more patients while still offering substantial
benefit to all, with little added structural costs. Health
data can also be used to evaluate promising knowledge
translation initiatives.
Health data can be useful in auditing the technical
process of cancer control for patient safety and quality
control. A high level of technical expertise is required to
perform cancer surgery, palliate cancer symptoms effec-
tively, treat with radiation accurately and safely adminis-
ter chemotherapy. Rates of medical error and factors
associated with medical error in cancer treatment in
developing countries are largely unknown. A compre-
hensive review of the literature by the Radiotherapy
Safety Team within the World Alliance for Patient
Safety found no detailed reports from Africa or Asia on
adverse events from radiotherapy [67]. One audit of a
new radiotherapy centre in a developing country in Asia
found that 52% of audited patients received sub-optimal
radiation treatment, potentially leading to compromised
cure or palliation or serious treatment toxicity [68].
Inadequate skills and knowledge, lack of a formal quality
assurance process or peer review process and heavy
workload were identified as barriers to quality. One
approach to ameliorating deficiencies is regular treat-
ment audit. This can be enabling for oncology staff and
allow targeted continuing medical education [68].
Health Data for Quality Cancer Control in Developing
Countries: Outcome
Collection of health care data allows outcome assess-
ment of cancer control programs. This includes trending
changes in an outcome such as cancer incidence or sur-
vival over time, or following geographic variations in
incidence of a given cancer. Health data can help assess
effectiveness, access to care, equitability of structure,
process and outcome, sustainability and economic effi-
ciency. In the following section, we will discuss the
assessment of effectiveness and economic efficiency as
examples. Regarding access and equity, we would briefly
mention that methodologies to identify the poor in
developing countries do exist, though to our knowledge,
they have not been used as part of outcome assessments
of cancer control in developing countries [69].
Without health data collection on structure, process
and outcome, it will not be possible to effectively evalu-
ate innovative program’s effectiveness. For instance,
Datta and Rajasekar suggest a three-tier model for pro-
vision of radiotherapy services for India [70]. They
describe three levels of treatment capacity with smaller
centres in the periphery electronically linked to more
comprehensively equipped centres. As another example,
the role of primary community health care workers in
improving cancer control deserves further investigation.
Their beneficial roles could include coordinating cancer
care, ensuring timely referral, optimizing access, ensur-
ing equitability and maximizing prevention, early detec-
tion, follow-up and palliative care of cancer patients.
Without health data on structure, process and out-
come, we cannot know if all programs and protocols
that have been successful in wealthy settings will work
as well in limited-resource settings [71]. This highlights
the need for population-based effectiveness studies in
developing countries [72]. Early evidence suggests that
developed world protocols are not always as successful
in developing world settings, probably due to a mix of
patient-related, tumour-related, treatment-related and
system-related factors [73-75]. Magrath et al found a
higher rate of toxic deaths in their experience treating
acute lymphoblastic leukemia in India compared to ser-
ies from developed countries [73]. They hypothesized
this was due to a combination of more extensive disease
at diagnosis, delay in diagnosis, co-morbidity such as
infection, differences in achievable home hygiene and
poor access to acute and supportive care. The authors
also noted large differences in regional leukemia genet-
ics compared to Western series.
With limited resources, achieving the greatest health
benefit with available resources is an important outcome
of health systems. The vast majority of economic ana-
lyses for cancer treatment, palliation, screening and
early detection are from developed countries [76].
Though there are clearly many cost-effective interven-
tions that oncologists use in developed countries, their
cost-effectiveness in specific resource-limited settings is
usually not known [77]. As both cost and effectiveness
of an intervention can be different in developing coun-
tries compared to developed countries, these must be
measured and taken into account before determining
whether an intervention would be cost-effective for a
specific limited-resource country.
One example where an economic analysis has been
done for developing countries is from the Breast Health
Global Initiative (BHGI). BHGI produced regional esti-
mates on the cost-effectiveness of treating breast cancer,
comparing results for Africa, Asia and North America.
The cost-effectiveness ratios for treating early-stage
breast cancer versus not treating it were $78, $62 and
Hanna and Kangolle BMC International Health and Human Rights 2010, 10:24
http://www.biomedcentral.com/1472-698X/10/24
Page 7 of 11$1960 per disability adjusted life-year (DALY) averted
for the African, Asian and North American regions
respectively [78]. A comprehensive breast cancer treat-
ment program that treated early and advanced stages of
breast cancer and involved early detection would cost
$75, $75 and $915 per DALY averted in these respective
regions.
Similarly, cost per fraction of radiation is highly sensi-
tive to context. A single fraction of radiation has been
estimated to cost $35 to deliver by a cobalt machine in
the Netherlands versus $2 in China or India [79]. This
relates to differences in the yearly number of fractions
of radiation delivered per radiation machine, cost of
quality assurance and machine maintenance as well as
differences in capital cost of cobalt radiation machines.
We would highlight the need for international coopera-
tion and innovation to modify currently prohibitive
radiation machine costs for developing countries.
Cost-effectiveness of cancer prevention and early
d e t e c t i o ni nL o w -a n dM i d d l e - I n c o m eC o u n t r i e sh a s
been assessed in some cases. Cervical cancer screening
with visual inspection with acetic acid (VIA) with a one-
visit twice-in-a-lifetime approach costs $91 per year of
life saved in India and $319 per year of life saved in
Kenya [80]. The authors place these figures in perspec-
tive by noting that a single lifetime screening with VIA
is as cost-effective as hepatitis B vaccination in India
and malaria prevention using bed nets in Kenya.
Methods and criteria for economic assessment of can-
cer treatments in low-resource settings are developing.
As suggested by the Commission of Economics and
Health, one approach is to assess the cost-appropriate-
ness of a treatment by comparing the incremental cost
per disability-adjusted life-year averted to the country’s
per capita gross domestic product (GDP) [76,81]. Using
a similar method, Rawlins found that none of the 26
modern chemotherapy regimens assessed were cost-
effective in 12 of 13 Low- and Middle-Income Asia-
Pacific countries [82]. It is important to note these cal-
culations assume drug costs are the same in developing
countries as in the UK. Rawlins’ findings emphasize the
need for global action on appropriate cancer drug prices
for developing countries.
The WHO-CHOICE program has also developed a
method referred to as generalized cost-effectiveness ana-
lysis [83]. It allows for region-specific cost-effectiveness
estimation. This can be of use to a developing country
currently unable to afford the multiple economic ana-
lyses needed on numerous health interventions. The
analysis of cost-effectiveness of breast cancer interven-
t i o n sb yB H G Ii so n ee x a m p l eo fs u c ha na n a l y s i s .A s
another example, four interventions for tobacco control
requiring government action were found cost-effective
in most world regions using this methodology: taxation,
clean indoor air laws, a comprehensive ban on advertis-
ing and information dissemination on the risks to health
of tobacco [84]. Nicotine replacement also fell within
the realm of cost-effective for many regions using the
cut-off of cost per DALY averted of less than three
times GDP per capita [84]. These modeled results do
not eliminate the need for country-specific cost-effec-
tiveness analyses but can be complimentary to them,
helping inform decision making and sectoral debates on
resource allocation [85].
Health Data for Quality Cancer Control in Developing
Countries: Summary
Greater investment in cancer control paired with the
use of health data to guide and optimize investment
holds the promise of improved cancer outcomes in
developing countries. The benefits of health data for
quality cancer control are summarized in table 1.
Capacity for Health Services Research in Developing
Countries
In addition to limitations in data availability, there is
limited human capacity in Low- and Middle-Income
Countries to produce health services and policy research
[86]. Organizations such as AfrOx, the International
Agency for Research on Cancer (IARC), the Interna-
tional Union Against Cancer (UICC) and others are sup-
porting development of health services research capacity
in developing countries. As mentioned previously, there
has been a renewed commitment to improving health
systems data in developing countries by many of the lar-
gest global health agencies [55].
Gonzalez Block and Mills suggest that 0.1% of total
health care expenditure should be spent on health ser-
vices and policy research in developing countries [86].
On average, current expenditure in developing countries
is estimated to be 0.007% of total health care expendi-
ture, 14 times below this recommended norm. There is
a great need for ongoing national and international sup-
port to build health services research capacity in devel-
oping countries. The international health services and
policy research community has much to offer in helping
achieve this.
Summary
In most developing countries, there are large knowledge
gaps in the description of oncology structure, process
and outcome. Where information is available, it demon-
strates a picture of great need. Access to care and qual-
i t yo fc a r em u s tb ei m p r o v e da n de c o n o m i ce f f i c i e n c i e s
gained. Investment in cancer control for developing
countries is desperately needed. We would recommend
four linked priorities to optimize this investment: (1)
National and regional capacity building in health
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Informed investment in higher quality health data
sources. (3) More economic evaluations relevant to
oncology in developing countries. (4) Research into
effective and cohesive models of cancer control appro-
priate to developing countries. Achieving these will
require increased national, regional and international
collaboration and political leadership. These four priori-
ties are similar to goals for the global cardiovascular
research community and reflect the call to action of
eight of the largest global health agencies on health data
[55,87]. We strongly support achievement of these prio-
rities within the scope of health information systems
and research agendas that cover the full scope of health
conditions afflicting developing countries (horizontal
integration). Health services research has an irreplace-
able role in oncology for developing countries, equip-
ping health systems to optimally and efficiently prevent
the preventable, detect cancer as early as possible, cure
the curable, and to relieve the intense suffering caused
by cancer among those in need.
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